15,457 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Acquired by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,457 shares of the company’s stock, valued at approximately $81,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Inozyme Pharma by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after acquiring an additional 33,998 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Inozyme Pharma by 40.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock worth $20,242,000 after purchasing an additional 756,717 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in shares of Inozyme Pharma by 52.2% during the first quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after purchasing an additional 150,120 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma in the second quarter valued at about $76,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Inozyme Pharma by 16.1% in the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock valued at $851,000 after buying an additional 26,464 shares in the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on INZY. Stifel Nicolaus initiated coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Inozyme Pharma in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday. Jefferies Financial Group restated a “buy” rating and set a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $15.00 price target on shares of Inozyme Pharma in a research note on Monday, September 30th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $16.14.

Inozyme Pharma Stock Performance

Shares of INZY stock opened at $4.78 on Tuesday. The stock has a market capitalization of $299.85 million, a price-to-earnings ratio of -3.27 and a beta of 1.51. Inozyme Pharma, Inc. has a one year low of $2.70 and a one year high of $7.80. The company’s 50-day simple moving average is $5.29 and its 200-day simple moving average is $4.95. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, August 6th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Equities analysts anticipate that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current fiscal year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.